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Why this topic?

Learning Objectives
●
●
●
●

Appreciate the signiﬁcance of addressing smoking cessation
Learn a brief interventional model for cessation counseling
How to structure a quit plan
Understand the role/risks/beneﬁts of
○
○
○

Pharmacologic therapy
Behavioral therapy
Electronic cigarettes

● Learn practical tips and hear sample language
● Watch a sample intervention

Won’t be Covering
●
●
●
●

Pregnant adults
Teens
Children
Motivational Interviewing

Case 1
Mr. M is a 57 yo M with DM2, HLD, COPD who presents to establish care.
Your MA marked him as a current smoker.
You learn he has smoked for 20 years, 1 pack a day.
You are already running 30 minutes behind and have another patient roomed.
Do you travel down the road of smoking cessation?

Tobacco is the
leading preventable
cause of disease,
disability, and death
in the U.S.

480,000 deaths
annually

In 2019,
20% of US adults
used tobacco (50
million).
14% of smoked cigarettes
6% used e-cigarettes

70% of cigarette
smokers see a
clinician annually
70% of adults who smoked
reported they wanted to stop

Only 30% of tobacco users
leave a health care visit with
evidence-based counseling
or medications

Addressing
smoking cessation
increases patient
satisfaction.

Disparities in Tobacco Use

Communication Models
Brief Assessment + Brief Intervention
●
●
●

The 5A’s
“Ask, Advise, Refer”
Motivational Interviewing

5 A’s of Smoking Cessation
Ask about tobacco use at every visit
Advise to quit in a clear and personalized manner
Assess willingness/readiness to quit
Assist with the quit attempt
Arrange follow-up and support

Ask
All patients about tobacco use at every visit
Identify/verify use
Treat as a “vital sign”

“Do you use tobacco products, for
example cigarettes or
e-cigarettes?”

5 A’s of Smoking Cessation
Ask about tobacco use at every visit
Advise to quit in a clear and personalized manner
Assess willingness/readiness to quit
Assist with the quit attempt
Arrange follow-up and support

“ Quitting is the most important thing you can
do for your health. As someone who cares
about you and your health, I’d like to help you
quit.”

Advise
Clear
Strong
Personalized

“As your physician, I need you to know that
quitting smoking is the most important thing
you can do to protect your health now and in
the future. The clinic staff and I can help you.”
“While smoking less is better, occasional or
light smoking is still dangerous. Our ultimate
goal should be to quit.”
“Continuing to smoke makes your asthma
worse and quitting may drastically improve
your health.”
“I know your a busy parent. Quitting smoking
may reduce the number of ear infections and
doctor’s visits your child has.”

5 A’s of Smoking Cessation
Ask about tobacco use at every visit
Advise to quit in a clear and personalized manner
Assess willingness/readiness to quit
Assist with the quit attempt
Arrange follow-up and support

“Would you be willing to quit within the
next month if I provide help for you?”

Assess
State of change
Direct vs open

“Quitting can be hard and it often takes
several tries to quit successfully.
Would you like to try again now? ”

“I’d like to hear your thoughts about
quitting?”

Case 1: Mr. M
Mr M has actually been considering quitting smoking since he got sick with
pneumonia this year. He is willing to try quitting and would like your help.
Where do you start?

5 A’s of Smoking Cessation
Ask about tobacco use at every visit
Advise to quit in a clear and personalized manner
Assess willingness/readiness to quit
Assist with the quit attempt
Arrange follow-up and support

1. Quit Plan

Assist

2. Medications

3. Practical counseling

Tobacco Use History
1.

2.

Smoking dependence
● How much are you smoking?
● How soon after waking up do you
smoke?

3. Potential Challenges

Med dosing

Practical counseling, problem-solving

Prior quit attempts
● Have you been able to quit before?
● What has worked for you in the past?

4. Identify motivations

Quit plan

●
●

●

What was diﬃcult for you?
Was there any trigger that made you go
back to smoking?

Why do you want to quit?

Document and re-address on follow-up

Quit Plan
STAR protocol:
-

Set a quit date (or taper plan)
Tell family, friends, co-workers; ask for their support
Anticipate challenges
Remove tobacco products from environment

Cold Turkey vs Taper
● Some evidence abrupt stop = higher success

● Individualized
- Prior attempts
- Degree of dependence

● Ask patient preference!

“What do you think will work for you?”
“What would you feel comfortable with?”

Case 1: Mr. M
Mr. M has never had any prior quit attempts. He wants to quit in the next 2 weeks.
When you bring up medications, he says he’s interested in hearing his options.

How do you counsel him on pharmaceutical treatment?

Medication
Long acting -- blunts baseline
withdrawal symptoms
1. Nicotine Patch
2. Varenicline*
3. Bupropion SR*

Short acting -- controls cravings
1.
2.
3.
4.

Lozenge
Gum
Inhaler
Nasal Spray

*Non-nicotine pill

General approach: combination therapy of long acting + short acting
“Basal- Bolus” or “Controller-rescue”

Nicotine Patch
MOA: Long acting NRT. Delivers baseline degree
of nicotine to blunt withdrawal symptoms.

Side Effects:
Skin irritation→ apply to different area daily

Dosing: 7mg, 14mg, 21 mg
-

>10 cig/day: 21 mg
<10 cig/day: 14mg
<5 cig/day: start with short-acting

*Common to underdose, be liberal
Duration: 3 months - 1 year
Taper: non-exact science
Apply in AM, change daily
Leave on if still smoking

Vivid dreams (20%) → always warn, can remove
overnight

Short Acting Nicotine Replacement Therapy (NRT)

MOA: Delivers faster burst of nicotine, controls cravings
Which one works best?
-

2018 Meta-analysis (136 studies, n= 64,000)
Comparing different types of NRT
Results: all forms effective
Overall, increased quit rate by 50%

Nicotine Mini Lozenge
Used instead of patch for <5 cigs per day
Compared to traditional lozenge:
-

More palatable
Less GI distress
Dissolves better -> rapid serum levels

Dose: 2mg, 4mg
-

If smokes within 30 mins waking : 4mg
If smokes later: 2mg

Counseling:
-

Don’t chew. Place in mouth. Let dissolve.
Get ahead of cravings! (Takes 1 hour to
affect serum nicotine level)
Use frequently (up to 20 daily)
OTC

SE: minimal

Nicotine Gum
Dose: 2mg, 4mg
-

If smokes within 30 mins waking :
4mg
If smokes later: 2mg

Frequency
-

Every 1-2 hours + with urge to smoke
Up to 24 pieces/day
Stay ahead of cravings with
scheduled doses

Counseling:
-

Absorbed through buccal mucosa
Chew sparingly
Park for total ~20 min
Avoid soda, coffee, alcohol (needs
alkaline environment)
Avoid with dentures
OTC

SE: GI irritation if swallowed

Less used NRT (require prescriptions)
Nasal Spray
-

Con: Least tolerated, nasal/throat
irritation
Pro: Fastest acting

Inhaler
-

Mimics hand-to-mouth habit
Puff, don’t inhale (uses buccal
mucosa)

Nicotine Replacement Therapy- Summary Points
→ Combination NRT is most successful
-

Single NRT : doubles success rate
Combination NRT: triples success

→ Use basal-bolus method
→ Warn about vivid dreams (all), skin irritation (patch)
→ Lozenge and gum: absorbed through cheek, use 4mg dose if smokes
within 30 mins of waking
→ Underdosing is common.

Case 1: Mr. M
-

Started on 21 mg patch (smokes 1 ppd)
Started on 4mg mini lozenge (smokes upon waking)

On follow-up, relapsed due to stress at work.
What else can we offer him?

Medication
Long acting -- blunt baseline
withdrawal symptoms
1. Nicotine Patch
2. Varenicline*
3. Bupropion SR*

*Non-nicotine pill

Short acting -- control cravings
1.
2.
3.
4.

Lozenge
Gum
Inhaler
Nasal Spray

Varenicline (Chantix)
MOA: Nicotine antagonist and agonist
Effect: Triples chances of success
Dosing:
-

Begin starter pack 1 week before quit date
Days 1-3: 0.5mg daily
Days 4-7: 0.5mg BID
Day 8: QUIT, 1mg BID
Reﬁll 1mg BID pack

Duration: 3-6 months, can take longer
SE:
-

Nausea- improves, take w/ food
Vivid dreams/insomnia- avoid before bed
Anxiety, irritability

Chantix and Mental Health
EAGLES Trial
-

Lancet 2016 RCT, n=2000
Randomized to varenicline, bupropion,
patch, placebo
50% patients w/ stable psych conditions
Result: No difference in psychiatric AE
among groups

→ BLACK BOX WARNING REMOVED in 2016!

A stable psychiatric condition in NOT a contraindication to any smoking
cessation medication.

Sustained Release Bupropion
Wellbutrin SR, Zyban
MOA: Neuronal reuptake inhibitor of NE and
dopamine
Effect: Doubles chances of quitting
For coexisting depression, weight gain
concern
Dose:
-

Start 1 week before quit date
Days 1-3: 150mg daily
Day 4: 150mg bid

Duration: 3 mo - year

SE:
-

-

Lowers seizure threshold
- Contraindication: seizure hx,
heavy ETOH use
Insomnia
Dry mouth
Anxiety/Irritability

Non-NRT Therapies - Summary Points
→ Can be used in combination (eg: varenicline + combination NRT)
→ Varenicline:
- Most effective option (even better with NRT)
- Safe with psychiatric history
→ Bupropion
- Avoid if seizure history or threshold lowering medication
→ Start both 1 week before quit date

Electronic Cigarettes

Nicotine + combustion products
(chemicals, carcinogens)

Less toxic, not harmless
Unknown long-term effects
E-cig or Vaping Use Associated Lung Injury
(EVALI)

Electronic Cigarettes

2019 NEJM RCT randomized 900 ppl (e-cig or NRT)
-

Given e-cig starter pack or NRT of choice
Abstinence rates at 1 year double in e-cig group (18% vs 9%)
- 80% e-cig group still vaping
- 9% still using NRT

Electronic Cigarettes: What do we tell our patients?
2021 USPSTF Final Recommendation Statement for Tobacco Cessation Interventions

1.
2.

Prioritize FDA approved medications ﬁrst
Vaping = harm reduction if standard treatment failed

Electronic Cigarettes: Counseling
1. Stop combustible tobacco
completely

A complete switch

2. Establish e-cigarette quit date
or taper plan

Finite period of use

Common
Concerns
Withdrawal Symptoms
Cravings
Triggers

Resistance to medication
Know your odds.

Self quit: 10% success
Nicotine replacement: 20% success
Combination nicotine replacement: 30%
Varenicline: 30% success
Bupropion: 20% success

Weight Gain
Be honest.
5-10 lb gain is common.
Emphasize use of mini lozenge/gum (appetite suppressant)

Withdrawal Symptoms (1 week)
Coping Strategies
Anxiety/ Irritability

Exercise regularly

Sleep problems

Go for a walk

Restlessness

Avoid late caffeine

Hunger

Focus on a hobby, clean the
house, call a friend
Drink more water

Cravings (months - years)

Triggers/Pitfalls
Coping Strategies
Alcohol

Avoid alcohol for the ﬁrst month

Environment

Encourage those around you to
quit/ not smoke around you

Social situations

Avoid places where you buy
tobacco, use tobacco, take a
different route to work
Get rid of cues (lighters, ashtrays)

Case 1: Mr. M
-

Avoid vaping
Instead, add varenicline to his combination NRT (triple chance of success)
Discussed weight gain and controlling cravings

What else can we do to increase chances of success?

5 A’s of Smoking Cessation
Ask about tobacco use at every visit
Advise to quit in a clear and personalized manner
Assess willingness/readiness to quit
Assist with the quit attempt
Arrange follow-up and support

● Use technology

Arrange
● Know local resources
Close follow-up
Refer to supplemental
resources/counseling

1-800-QUIT-NOW / PA Free Quitline
Phone and/or web based program
-

Coaching
Free nicotine replacement therapy
Educational materials

English, Spanish, Arabic
To enroll:
1.
2.

Web Intake: PA Free Quitline online, QuitLogix
Call 1-800-QUIT-NOW

Smokefree.gov
SmokefreeTXT

Text QUIT to 47848

3-5 messages/day
Over 6-8 wks

Doubles chances of
success!

Local Resources
JeffQuit
Myrna Brind Center for Mindfulness
Weekly group sessions, individual
support/coaching, medication support,
hypnosis
$249, 3 weeks
Penn Stop: Penn’s Comprehensive
Smoking Treatment Program
Penn Lung Center
Temple Smoking Cessation Program
Temple Lung Center

JFMA Behavioral Health Counselors
- Motivational Interviewing
- Stress management
- Social isolation
JFMA Social Work
- Socioeconomic stressors
- Housing instability
- Financial pressures

Smartphrases
.SMOKINGHISTORY

.SMOKINGCESSATIONPLAN

.SMOKINGCESSATIONBASICS

.SMOKINGCESSATIONAIDAVS

https://www.who.int/tobacco/quitting/training-for-primary-care-providers/en/

Case 2: The 5A’s in Practice
https://www.youtube.com/watch?v=yzWfgjXsgr4&ab_channel=QuitNowBC

Questions?
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